Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:35:12 16/07/2024 BST			5-day change	1st Jan Change
0.2675 ^EUR	-0.37%		-2.37%	-31.41%

04-04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Celyad Announces Registration of the First Patient in the Belgian THINK Trial

January 09, 2017 at 01:04 pm

Celyad announced that the first patient of the Therapeutic Immunotherapy with NKR-2 (THINK) trial started cell processing in Belgium. Blood was collected from this patient and first CAR-T NKR-2 dose level infusion (3x10 cells) is expected in January 2017.

Latest news about Celyad Oncology SA

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	02-09	MT
Celyad Oncology CEO Resigns	12-05	MT
Celyad Oncology CEO Steps Down for Personal Reasons	12-04	MT
Celyad Oncology SA Announces Executive Change	12-04	CI
Celyad Oncology Sa Announces Executive Change	12-04	CI
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	11-13	CI
Celyad Oncology to Cancel American Depository Receipt Program in October	26/09/23	MT
Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023	05/09/23
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	04/09/23	CI
Celyad Oncology Secures EUR10 Million via Private Placement With Historical Investors	25/08/23	MT
Celyad Oncology SA announced that it expects to receive ?9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors	23/08/23	CI
Celyad Oncology SA(OTCUS:CYAD.Y) dropped from NASDAQ Composite Index	18/05/23	CI
Global markets live: Boohoo, KBC, Vodafone, Home Depot, Ford...	16/05/23
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq	16/05/23	MT
Celyad Oncology Receives Delisting Notice From Nasdaq	15/05/23	MT
Forecast-Beating Apple Results Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	05/05/23	MT
Belgium's Celyad Oncology to Delist ASDs from Nasdaq	05/05/23	MT
Celyad Oncology to Delist From Nasdaq Global Market	05/05/23	MT
Celyad Oncology in Breach of Nasdaq's Listing Rule	04/04/23	MT
Transcript : Celyad Oncology SA, 2022 Earnings Call, Mar 24, 2023	24/03/23
Celyad Oncology SA Appoints Georges Rawadi as its New Chief Executive Officer	24/03/23	CI
Celyad Oncology Names Georges Rawadi as Chief Executive	24/03/23	MT
Celyad Oncology Appoints New CEO	24/03/23	MT
Celyad Oncology SA Auditor Raises 'Going Concern' Doubt	22/03/23	CI

Chart Celyad Oncology SA

Duration

Period

More charts

Company Profile

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Sector

Biotechnology & Medical Research

Calendar

20/09/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELYAD ONCOLOGY SA	-31.41%	12.14M
MODERNA, INC.	+24.85%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.26%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.08%	32.4B
ICON PUBLIC LIMITED COMPANY	+21.05%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.97%	14.52B
MEDPACE HOLDINGS, INC.	+47.32%	13.74B
BIO-TECHNE CORPORATION	+3.07%	12.17B

Other Biotechnology & Medical Research